-
-
-
-
-
-
-
Pfizer drug combination cuts prostate cancer progression risk by 52%
-
-
-
-
-
-
-
Pfizer and Innovent Biologics Enter Global Strategic Collaboration to Accelerate Development of Innovative Oncology Medicines
-
-
-
-
-
-
-
Pfizer beats first quarter estimates on strong product growth
-
-
-
-
-
-
-
Bristol Myers Squibb and Pfizer partner with Mark Cuban's Cost Plus Drugs
-
-
-
-
-
-
-
Pfizer Invites Public to View and Listen to Webcast of May 5 Conference Call with Analysts
-
-
-
-
-
-
-
Pfizer's trispecific antibody shows positive results in atopic dermatitis
-
-
-
-
-
-
-
U.S. FDA Grants Full Approval to Pfizer’s BRAFTOVI Combination Regimen in First-Line Metastatic Colorectal Cancer
-
1,198,707 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

